| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Levocarnitine propionate hydrochloride does not have a specific receptor target. It functions as a carrier of fatty acids into the mitochondria, facilitating their oxidation for energy production. It may also have antioxidant properties and improve endothelial function.
|
|---|---|
| ln Vitro |
Levocarnitine propionate is a derivative of L-carnitine. It facilitates the transport of long-chain fatty acids into the mitochondrial matrix for β-oxidation, thereby playing a key role in energy metabolism. It has been shown to improve exercise performance and reduce symptoms of peripheral arterial disease.
|
| ln Vivo |
In vivo, Levocarnitine propionate has been investigated for the treatment of peripheral arterial disease and other cardiovascular conditions. It has been shown to improve walking distance in patients with intermittent claudication. Its effects are attributed to improved fatty acid metabolism and energy production.
|
| Enzyme Assay |
In vitro assays for Levocarnitine propionate hydrochloride are not typically performed, as it is a metabolic agent rather than a drug targeting a specific enzyme or receptor. Its role in fatty acid oxidation can be studied in isolated mitochondria or in cell culture by measuring fatty acid oxidation rates.
|
| Cell Assay |
In vitro cell-based assays for Levocarnitine propionate hydrochloride are performed to study its effects on cellular energy metabolism. Cells are treated with the compound, and parameters such as oxygen consumption rate, fatty acid oxidation, and ATP production are measured. Its effects on endothelial cell function can also be assessed.
|
| Animal Protocol |
In vivo animal studies for Levocarnitine propionate hydrochloride are conducted in models of peripheral arterial disease, heart failure, or metabolic disorders. The compound is administered to rodents, and parameters such as exercise tolerance, cardiac function, or metabolic parameters are measured.
|
| ADME/Pharmacokinetics |
Levocarnitine propionate hydrochloride has a molecular weight of 253.72 and a molecular formula of C10H20ClNO4. As a hydrochloride salt, it is expected to have good aqueous solubility. It should be stored as powder at room temperature, protected from moisture.
|
| Toxicity/Toxicokinetics |
No specific toxicity data are documented for Levocarnitine propionate hydrochloride in the provided sources. As a derivative of L-carnitine, it is generally considered safe and well-tolerated. It has been investigated in clinical trials for peripheral arterial disease.
|
| Additional Infomation |
Levocarnitine propionate hydrochloride is a propionyl ester of L-carnitine. It has been investigated for the treatment of peripheral arterial disease and other cardiovascular conditions. It plays a role in fatty acid metabolism. It is for research use only.
|
| Molecular Formula |
C10H21CLNO4
|
|---|---|
| Molecular Weight |
254.7310
|
| Exact Mass |
253.108
|
| CAS # |
119793-66-7
|
| Related CAS # |
Propionyl-DL-carnitine chloride;18828-58-5;Levocarnitine propionate-d3 hydrochloride;1334532-19-2;Levocarnitine propionate-d5 hydrochloride
|
| PubChem CID |
157836
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
165-167°C
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
16
|
| Complexity |
232
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
Cl[H].O(C(C([H])([H])C([H])([H])[H])=O)[C@]([H])(C([H])([H])C(=O)O[H])C([H])([H])[N+](C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H]
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~985.34 mM)
H2O : ~60 mg/mL (~236.48 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (8.20 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (8.20 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (8.20 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (394.14 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9257 mL | 19.6286 mL | 39.2573 mL | |
| 5 mM | 0.7851 mL | 3.9257 mL | 7.8515 mL | |
| 10 mM | 0.3926 mL | 1.9629 mL | 3.9257 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
